MTOR and cardiac hypertrophy: showed that administration of r-irisin could attenuate angiotensin II (Ang II)–induced cardiomyocyte hypertrophy, in vitro, and that treatment of irisin in transverse aortic constriction (TAC)–induced cardiac hypertrophy murine, in vivo, significantly suppressed cardiac hypertrophy and fibrosis by phosphorylating AMPK (Thr172) and inhibiting the phosphorylation of mTOR (Ser2448).